INTERNATIONAL MYELOMA SOCIETY
19th International Myeloma Society Annual Meeting25-27 August, Los Angeles
N. Poster
Poster title
Applicant name
Status
 |
|
|
|
| P-03 | A first-in-human phase 1 study of oral LOXO-338, a ive BCL2 inhibitor, in patients with advanced hematologic malignancies (trial in progress) | NAIMAH BOLAJI |  Received |
 |
|||
| P-04 | Successful Ex-plantation of Left Ventricular Assist Device After Cardiac Recovery with Daratumumab Therapy in a Patient with End Stage Heart Failure due to Immunoglobulin Light-chain (AL) Amyloidosis | Daryl Tan | Received |
|
|||
| P-06 | Real World Experience of Patients Treated With Idecabtagene Vicleucel: A BCMA-Directed Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma | Annie Hayes | Received |
|
|||
| P-12 | Cevostamab is efficacious and well tolerated in patients aged 65 and =65 years with relapsed/refractory multiple myeloma (RRMM) | James Bailey | Received |
|
|||
| P-18 | Optimized affinity CD38 CAR-NK cells with CD38 KO show promising in-vivo activity in a Multiple Myeloma model | Michael ODwyer | Received |
|
|||
| P-21 | 7C6 is a novel monoclonal antibody that induces enhanced anti-myeloma activity of cytokine induced memory-like (CIML) NK cells by blocking MICA/B shedding and antibody-dependent cell cytotoxicity | Sabrin Tahri | Received |
|
|||
| P-25 | Investigating the effect of irreversible proteasome inhibitor Carfilzomib in in vivo models of Cardiometabolic Syndrome and early stage HFrEF. Prophylactic role of Metformin. | Evangelos Terpos | Received |
|
|||
| P-31 | Artificial intelligence analysis of whole-body magnetic resonance imaging of patients with multiple myeloma to find prognostic factors | Hiroyuki Takamatsu | Received |
|
|||
| P-32 | Lenalidomide maintenance after autologous hematopoetic stem cell transplantation in Hungary from 2016 to 2021 | Viktor Lakatos | Received |
|
|||
| P-42 | Phase 1 dose-escalation study of sotatercept in combination with lenalidomide and dexamethasone or pomalidomide and dexamethasone in relapsed/refractory multiple myeloma | Andrew Yee | Received |
|
|||
| P-43 | Prospective Assessment of Tumour Burden and Bone Disease in Plasma Cell Dyscrasias using DW-MRI and Exploratory Bone Biomarkers | Gaurav Agarwal | Received |
|
|||
| P-46 | Maintenance Therapy Cessation for Patients with Three-Year Sustained MRD Negative Remissions: Initial Results from a Phase II Study | Neha Korde | Received |
|
|||
| P-51 | Sustained Bone Marrow and Imaging MRD negativity as indicators to discontinue lenalidomide maintenance after ASCT; preliminary results of a single-center prospective cohort study | Panagiotis Malandrakis | Received |
|
|||
| P-57 | Studying microRNAs from Extracellular Vesicles as potential biomarkers in liquid biopsies of Multiple Myeloma patients | Rui Bergantim | Received |
|
|||
| P-58 | Identifying microRNAs as potential biomarkers of drug resistance in Multiple Myeloma patients: proof-of-concept study | Rui Bergantim | Received |
|
|||
| P-62 | MAF translocations are enriched in high-risk NDMM patients with elevated levels of circulating tumor cells suggesting a genetic basis for the aggressive disease course | Cathelijne Fokkema | Received |
|
|||
| P-64 | Evaluation of single nucleotide variants of CDKN1A, TP53BP, and XRCC1 genes in multiple myeloma patients undergoing hematopoietic stem cells transplant and their association with treatment response. | David Garrido | Received |
|
|||
| P-65 | Development of a mass cytometry-based toolkit to investigate myeloma therapeutic responses ex vivo | Sarah Gooding | Received |
|
|||
| P-82 | Stromal cell - neutrophil interactions are driving a pro tumor environment in multiple myeloma | Madelon de Jong | Received |
|
|||
| P-91 | Thrombocytopenia with coagulation abnormality in multiple myeloma patients treated with proteasome inhibitor and/or immunomodulatory drugs. | Kazuhito Suzuki | Received |
|
|||
| P-92 | Impaired glutamine/glutamate metabolic axis into myeloma microenvironment affects osteoclast formation. | Nicola Giuliani | Received |
|
|||
| P-104 | Multi-omics data integration reveals molecular targets of carfilzomib resistance in multiple myeloma | Julia Huber | Received |
|
|||
| P-109 | ER-phagic Control of Lipid Metabolism Supports Multiple Myeloma Cell Survival | SIMONE CENCI | Received |
|
|||
| P-110 | Activity and tolerability of lenalidomide (LLD) is enhanced following low-dose continuous percutaneous delivery compared to once daily dosing in an NCIH929 MM Xenograft model in SCID mice | Jamie Oliver | Received |
|
|||
| P-111 | Targeting the Mitochondrial Protease ClpP Unveils Novel Vulnerabilities in Multiple Myeloma | SIMONE CENCI | Received |
|
|||
| P-112 | Anti-BCMA therapy in multiple myeloma. A single-center experience. | Borja Puertas Martínez | Received |
|
|||
| P-117 | High throughput metabolism related drug screening identifies hypoxia inducible factor-1 alpha as a promising therapeutic target in proteasome inhibitor resistant multiple myeloma | Philip Weir | Received |
|
|||
| P-122 | Racial Differences in Spinal Cord Compression Related Hospitalizations in Patients with Multiple Myeloma: A Population Based Study | Samer Al Hadidi | Received |
|
|||
| P-125 | Multiple myeloma in Reunion Island : a descriptive and pronostic study on newly diagnosed patients between 2015 and 2019. | Romain Chane-Teng | Received |
|
|||
| P-140 | Outreach and Satellite Transplant Clinics Increase Multiple Myeloma (MM) Transplant Referrals and Specifically Transplant Referrals of African American Patients | Anand Jillella | Received |
|
|||
| P-141 | Prognostic impact of CD3/CD34 ratio in apheresis collection in multiple myeloma patients undergoing autologous stem cell transplant | Marcella Kaddoura | Received |
|
|||
| P-143 | SLIM CRAB Criteria revisited: A meta-analysis of studies on biomarker defined early multiple myeloma | Heinz Ludwig | Received |
|
|||
| P-145 | The clinical significance of a MGUS Tumor Board | Sandy Mazzoni | Received |
|
|||
| P-146 | Screening Technique for M-proteins in Acetonitrile Precipitates of Serum using MALDI-TOF Mass Spectrometry: A Comparison with Serum Immunofixation Electrophoresis and Serum Free Light Chain Assay | Nikita Mehra | Received |
|
|||
| P-148 | Second booster BNT162b2 restores SARS-CoV-2 humoral response in patients with multiple myeloma, except for those under treatment with anti-BCMA agents | Ioannis Ntanasis-Stathopoulos | Received |
|
|||
| P-149 | Prevalence of type 1 Gaucher disease in patients with multiple myeloma: interim analysis of a prospective, multicentre, observational study | massimo offidani | Received |
|
|||
| P-150 | Identification of misclassified multiple myeloma patient risk subgroups with a novel biological disease stratifier | Afsaneh Panahi | Received |
|
|||
| P-151 | Primary Plasma cell Leukemia in Latin America: demographic, clinical, and prognostic characteristics. A study of GELAMM group. | Camila Peña | Received |
|
|||
| P-152 | Prevalence of Monoclonal Gammopathies in adult Uruguayan population | Lucia Pérez Baliero | Received |
|
|||
| P-153 | Impact of t(11;14) in multiple myeloma on response to treatment and survival. | Borja Puertas Martínez | Received |
|
|||
| P-156 | Evaluation of SAVED and IMPEDE-VTE Scoring Systems for Venous Thromboembolism Prophylaxis in Patients with Multiple Myeloma | Christopher Sandifer | Received |
|
|||
| P-157 | Carfilzomib (CFZ) resistance is associated with significant deregulation of the BH3 family proteins in multiple myeloma (MM) | Anja Schneller | Received |
|
|||
| P-158 | End-of-life treatment and treatment costs of multiple myeloma patients in a real-world setting: a retrospective analysis of 91 patients from diagnosis to death | Maarten Seefat | Received |
|
|||
| P-161 | Oral antivirals ritonavir-nirmatrelvir and molnupiravir are highly effective in patients with multiple myeloma and COVID-19; a single-center, prospective study | Vassiliki Spiliopoulou | Received |
|
|||
| P-163 | MORTALITY IN PATIENTS WITH MULTIPLE MYELOMA: THE MYLORD STUDY FROM THE FRENCH NATIONAL HEALTH DATA SYSTEM (SNDS) | Oana Mihailescu | Received |
|
|||
| P-178 | A Pilot Plant Based Dietary Intervention in MGUS And SMM is Feasible and Associated with Reduction in Insulin and Leptin Levels | Urvi Shah | Received |
|
|||
| P-179 | Comorbidities associated with Monoclonal Gammopathy of Undetermined Significance, Its Subtypes, and Risk Factors | Lawanya Singh | Received |
|
|||
| P-183 | Outcomes in Respiratory Tract Infections in Hospitalized Multiple Myeloma Patients with Asthma and Chronic Obstructive Pulmonary Disease | Kuldeepsinh Atodaria | Received |
|
|||
| P-188 | Moving from Research Priorities to Clinical Research: Implementing the Results of a Priority Setting Partnership on Multiple Myeloma | Samantha Fowler | Received |
|
|||
| P-190 | Bone Remineralization of Lytic Lesions in Newly Diagnosed Multiple Myeloma (NDMM) Patients Treated with Carfilzomib, Lenalidomide, Dexamethasone /- Daratumumab Induction Regimen | Carlyn Tan | Received |
|
|||
| P-191 | The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A systematic review | Hira Mian | Received |
|
|||
| P-192 | Patient Reported Outcome & Family Reported Outcome and The Most Correlated Clinical Measures Over One Year of Follow-Up | Kareem Midlig | Received |
|
|||
| P-197 | A glimpse into transplant-ineligible newly diagnosed multiple myeloma treatment in real-world practice in Spain. Carinae study | Gonzalez-Pardo Miriam | Received |
|
|||
| P-210 | IMPACT OF PRE-TRANSPLANT DISEASE STATUS AND POST-TRANSPLANT MAINTENANCE THERAPY ON SURVIVAL OUTCOMES IN PATIENTS WITH MULTIPLE MYELOMA UNDERGOING AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANT | Vinay Edlukudige Keshava | Received |
|
|||
| P-213 | Efficacy and Safety of Bortezomib in Once Weekly vs. Twice Weekly Dosing in the Treatment of Multiple Myeloma | Kwan-Keat Ang | Received |
|
|||
| P-215 | D-VTd as induction therapy in newly diagnosed multiple myeloma (NDMM) patients who are candidates for transplantation: A Real-Life Experience in a single center | Carmen Martínez Chamorro | Received |
|
|||
| P-218 | Real world experience of induction therapy for treatment of newly diagnosed multiple myeloma: an analysis from the Australian and New Zealand, and Asia-Pacific Myeloma and Related Diseases Registries. | Justin Ng | Received |
|
|||
| P-219 | Daratumumab (DARA) lenalidomide/bortezomib/dexamethasone (RVd) in Black patients with transplant-eligible newly diagnosed multiple myeloma (NDMM): an updated subgroup analysis of GRIFFIN | Mary Angelozzi | Received |
|
|||
| P-222 | A prospective phase 2 study to assess minimal residual disease after ixazomib plus lenalidomide plus dexamethasone (IRd) treatment for newly diagnosed transplant eligible multiple myeloma patients | Raija Silvennoinen | Received |
|
|||
| P-242 | Efficacy of Selinexor in Relapsed/Refractory Multiple Myeloma (RRMM) patients with del17p and other high-risk abnormalities (A retrospective single-center study) | HAMID EHSAN | Received |
|
|||
| P-247 | Addressing the Knowledge Gap to Optimize Treatment Sequencing for Patients With Relapsed/Refractory Multiple Myeloma | Elizabeth Heller | Received |
|
|||
| P-249 | Real world evidence and outcomes of patients who are exposed or refractory to lenalidomide at the time of first relapse: a Greek registry analysis | Sachin Patel | Received |
|
|||
| P-255 | Isatuximab Plus Pomalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM) in Real-Life Context: Interim Analysis of the Retrospective IMAGE Study | Mackenzie Baciuska | Received |
|
|||
| P-258 | Real-world Experience With Isatuximab in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): IONA-MM First Interim Analysis | Mackenzie Baciuska | Received |
|
|||
| P-260 | Daratumumab (DARA) Plus Bortezomib and Dexamethasone (D-Vd) or Lenalidomide and Dexamethasone (D-Rd) in Relapsed or Refractory Multiple Myeloma (RRMM): Subgroup Analyses of CASTOR and POLLUX | Nicole Triolo | Received |
|
|||
| P-266 | Favorable Outcomes of 3-weekly Daratumumab-based Regimens in Relapsed/Refractory Multiple Myeloma: Impact of MRD, Rapid Doubling Time, LDH, Triplets and Quadruplets | Cheong Ngai | Received |
|
|||
| P-267 | Subcutaneous Isatuximab Administration by An On-Body Delivery System in Combination with Pomalidomide-Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Interim Phase 1b Study Results | Vasudha Chachra | Received |
|
|||
| P-270 | GO41036: A Phase Ia/Ib open-label, multicenter study evaluating the safety and pharmacokinetics of tiragolumab in combination with atezolizumab and daratumumab in patients with R/R MM | James Bailey | Received |
|
|||
| P-277 | Carfilzomib, lenalidomide and dexamethasone followed by a second autologous hematopoietic cell transplantation is an effective strategy in first-relapsed multiple myeloma | Remi TILMONT | Received |
|
|||
| P-283 | TRIATLON - TRIple CLAss exposed/refractory MultipLe MyelOma PatieNts: A real world analysis (RWA) from the Austrian Myeloma Registry (AMR) | Wolfgang Willenbacher | Received |
|
|||
| P-284 | Updated progression-free survival (PFS) and depth of response in IKEMA, a randomized Phase 3 trial of isatuximab, carfilzomib and dexamethasone (Isa-Kd) vs Kd in relapsed multiple myeloma (MM) | MUKUL RASTOGI | Received |
|
|||
19th International Myeloma Society Annual Meeting
25-27 August, Los Angeles
Search and consult posters online
in an exclusive section
for each poster
in an exclusive section
for each poster
ACTIVE FROM 25/08/2022 TO 27/08/2022
Poster
Gallery
Gallery
Upload
Poster
Poster
Featured Poster
Vote poster
Poster Discussion
Forum
Forum
|
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress.
|
|
||
|
||||
Poster submission deadline 17/08/2022
|
|
